Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Hajime Uno, Ph.D.

Co-Author

This page shows the publications co-authored by Hajime Uno and Lee-Jen Wei.
Connection Strength

8.790
  1. Uno H, Schrag D, Kim DH, Tang D, Tian L, Rugo HS, Wei LJ. Assessing Clinical Equivalence in Oncology Biosimilar Trials With Time-to-Event Outcomes. JNCI Cancer Spectr. 2019 Dec; 3(4):pkz058.
    View in: PubMed
    Score: 0.921
  2. Uno H, Kim DH, Wei LJ. Interpreting the Association of First-in-Class Immune Checkpoint Inhibition and Targeted Therapy With Survival in Patients With Stage IV Melanoma. JAMA Oncol. 2018 08 01; 4(8):1135-1136.
    View in: PubMed
    Score: 0.860
  3. Uno H, Tian L, Wei LJ. Estimating and Interpreting the Overall Survival Benefit of Checkpoint Inhibitors via Meta-analysis. JAMA Oncol. 2018 08 01; 4(8):1137-1138.
    View in: PubMed
    Score: 0.860
  4. Uno H, Claggett B, Tian L, Fu H, Huang B, Kim DH, Wei LJ. Adding a new analytical procedure with clinical interpretation in the tool box of survival analysis. Ann Oncol. 2018 05 01; 29(5):1092-1094.
    View in: PubMed
    Score: 0.845
  5. Uno H, Hassett MJ, Wei LJ. Axillary vs Sentinel Lymph Node Dissection in Women With Invasive Breast Cancer. JAMA. 2018 01 16; 319(3):306.
    View in: PubMed
    Score: 0.828
  6. Uno H, Wittes J, Fu H, Solomon SD, Claggett B, Tian L, Cai T, Pfeffer MA, Evans SR, Wei LJ. Alternatives to Hazard Ratios for Comparing the Efficacy or Safety of Therapies in Noninferiority Studies. Ann Intern Med. 2015 Jul 21; 163(2):127-34.
    View in: PubMed
    Score: 0.697
  7. Uno H, Claggett B, Tian L, Inoue E, Gallo P, Miyata T, Schrag D, Takeuchi M, Uyama Y, Zhao L, Skali H, Solomon S, Jacobus S, Hughes M, Packer M, Wei LJ. Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. J Clin Oncol. 2014 Aug 01; 32(22):2380-5.
    View in: PubMed
    Score: 0.648
  8. Claggett B, Uno H, Wei LJ. Unifying Design and Analysis for Superiority and Noninferiority Trials With Appropriate End Point. JAMA Surg. 2019 05 01; 154(5):466-467.
    View in: PubMed
    Score: 0.226
  9. Horiguchi M, Tian L, Uno H, Cheng S, Kim DH, Schrag D, Wei LJ. Quantification of Long-term Survival Benefit in a Comparative Oncology Clinical Study. JAMA Oncol. 2018 06 01; 4(6):881-882.
    View in: PubMed
    Score: 0.212
  10. Fang X, Uno H, Wei LJ. Assessing Metronomic Chemotherapy for Progressive Pediatric Solid Malignant Tumors. JAMA Oncol. 2018 05 01; 4(5):743.
    View in: PubMed
    Score: 0.211
  11. Hasegawa T, Uno H, Wei LJ. Zoledronic Acid Dosing in Patients With Metastatic Breast Cancer. JAMA Oncol. 2018 04 01; 4(4):585.
    View in: PubMed
    Score: 0.210
  12. Horiguchi M, Uno H, Wei LJ. Evaluating Noninferiority With Clinically Interpretable Statistics for the PROSELICA Study to Assess Treatment Efficacy of a Reduced Dose of Cabazitaxel for Treating Metastatic Prostate Cancer. J Clin Oncol. 2018 03 10; 36(8):825-826.
    View in: PubMed
    Score: 0.207
  13. Horiguchi M, Uno H, Wei LJ. Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab as a Result of Adverse Events Lived Significantly Longer Than Patients Who Continued Treatment. J Clin Oncol. 2018 03 01; 36(7):720-721.
    View in: PubMed
    Score: 0.207
  14. Pak K, Uno H, Kim DH, Tian L, Kane RC, Takeuchi M, Fu H, Claggett B, Wei LJ. Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio. JAMA Oncol. 2017 12 01; 3(12):1692-1696.
    View in: PubMed
    Score: 0.205
  15. Kim DH, Uno H, Wei LJ. Restricted Mean Survival Time as a Measure to Interpret Clinical Trial Results. JAMA Cardiol. 2017 11 01; 2(11):1179-1180.
    View in: PubMed
    Score: 0.204
  16. Tian L, Fu H, Ruberg SJ, Uno H, Wei LJ. Efficiency of two sample tests via the restricted mean survival time for analyzing event time observations. Biometrics. 2018 06; 74(2):694-702.
    View in: PubMed
    Score: 0.202
  17. Horiguchi M, Uno H, Wei LJ. Overall Survival in the Randomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer. J Clin Oncol. 2017 10 10; 35(29):3373.
    View in: PubMed
    Score: 0.201
  18. Hasegawa T, Uno H, Wei LJ. How to Summarize the Safety Profile of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy? J Clin Oncol. 2016 11 01; 34(31):3818.
    View in: PubMed
    Score: 0.190
  19. Hasegawa T, Uno H, Wei LJ. Safety Study of Salmeterol in Asthma in Adults. N Engl J Med. 2016 09 15; 375(11):1097.
    View in: PubMed
    Score: 0.189
  20. Hasegawa T, Uno H, Wei LJ. Neratinib after trastuzumab in patients with HER2-positive breast cancer. Lancet Oncol. 2016 05; 17(5):e176.
    View in: PubMed
    Score: 0.184
  21. Hasegawa T, Uno H, Wei LJ. Nivolumab in Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2016 02 04; 374(5):492-3.
    View in: PubMed
    Score: 0.181
  22. Uno H, Wei LJ, Hughes M. Effects of bracing in adolescents with idiopathic scoliosis. N Engl J Med. 2014 02 13; 370(7):680.
    View in: PubMed
    Score: 0.158
  23. Zhao L, Tian L, Uno H, Solomon SD, Pfeffer MA, Schindler JS, Wei LJ. Utilizing the integrated difference of two survival functions to quantify the treatment contrast for designing, monitoring, and analyzing a comparative clinical study. Clin Trials. 2012 Oct; 9(5):570-7.
    View in: PubMed
    Score: 0.142
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.